14.05.2013
Nanotron Technologies Granted Patent Projection of Significant Wireless IP
Read more...28.02.2013
Nanotron Technologies launches revolutionary platform with swarm features
Read more...10.12.2012
Nanotron Technologies Allows In-House Logistic Tracking
Read more...06.12.2012
Two Posters and Two Oral Presentations on NOXXON Compounds at 2012 American Society of Hematology (ASH) Conference
Read more...04.12.2012
NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer® NOX-H94
Read more...Berlin, Germany- 5th January 2012 - NOXXON Pharma, a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers, announced today that it has been invited to present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Iain Buchanan, NOXXON’s Chief Executive Officer, will give a presentation on the company’s Spiegelmer technology and the current status of NOXXON’s drug pipeline which includes three compounds that will enter Phase II clinical studies in 2012.
The NOXXON presentation is scheduled for Tuesday, 10th January 2012 from 07:30-8:00 AM (Pacific Standard Time). The company presentation will take place in the room “Elizabethan C/D” at the Westin St. Francis Hotel in San Francisco.